Group 1: Core Points - The Beijing Stock Exchange (BSE) aims to provide a flexible and inclusive platform for innovative small and medium-sized enterprises (SMEs) to access financing, with listing requirements that differ from those of the Shanghai and Shenzhen exchanges [2][3] Group 2: Basic Listing Conditions - Companies must be listed on the New Third Board for at least 12 months as a prerequisite for BSE listing, with a requirement for compliant operations and no major legal violations in the past year [3] - BSE has established four differentiated financial standards, allowing companies to meet any one of them to qualify for listing [4][5][6][7] - The average market capitalization for new stocks on BSE is between 1.5 billion to 2 billion, with a public shareholding ratio requirement of at least 25% [8] Group 3: Industry Attributes and Negative List - BSE prioritizes support for innovative enterprises in advanced manufacturing, digital economy, green and low-carbon technologies, and biomedicine, with these sectors accounting for 78% of listed companies in 2024 [9] - Certain industries, such as finance and real estate, face strict restrictions, with companies in these sectors needing to divest certain assets to qualify for listing [10] Group 4: Corporate Governance and Compliance Requirements - Companies must have a clear ownership structure, with no changes in actual control in the past 24 months, and major shareholders must sign a concerted action agreement [11][12] - Internal control systems must comply with the Corporate Governance Code, particularly regarding related party transactions [13] - BSE employs a "precise inquiry" mechanism for information disclosure, requiring detailed descriptions of innovative features in the prospectus [14] Group 5: Review Process and Timeframes - The review process consists of four stages, including pre-communication, application acceptance, inquiry, and meeting stages, with an average approval rate of 83% under the registration system [15][18] - A "direct connection review" mechanism allows eligible companies to shorten the review period to four months [19] Group 6: Ongoing Supervision and Refinancing - Companies transitioning from the innovation layer to BSE enjoy a 24-month grace period, with annual reports required to include "specialized and innovative" indicators [21] - The limit for small and rapid financing has been raised to 300 million, with an average refinancing time of only 38 days in 2024, representing a 40% efficiency improvement over the Shanghai and Shenzhen markets [22] Group 7: Practical Suggestions - Companies are advised to initiate compliance rectification 12 months prior to listing, particularly regarding related party transactions [23] - The average price-to-earnings ratio for new stock issuances on BSE is between 18-25 times, with strategic timing for applications recommended [24] - Selecting intermediary institutions with successful BSE case experience is crucial, as leading brokerage firms have a project approval rate exceeding 90% [25] Group 8: Future Outlook - With the implementation of the "Deep Reform 19 Articles" in 2025, BSE is expected to further optimize listing standards and introduce a "green channel" for cutting-edge technology companies [26]

以下文章来源于非凡油条 ，作者豆腐乳儿 非凡油条 . 非凡油条新家 作者： 豆腐乳儿 来源： 非凡油条 中国第一大出口商品是什么？ 熟悉外贸的人可能会回答出口"旧三件"， 即服装、家电、家具 ；最近几年做外贸的朋友，则有 可能想到新崛起的出口"新三件"，即 电动汽车、锂离子电池、太阳能电池 。 但是这些答案都不正确。 按出口金额算，去年海关总署统计的中国第一大出口商品，是 集成电路 ，也就是这么多年里一 直喊着"卡脖子"的芯片。 ---------------------------------- 有人看了这张图，洋洋得意地说： "卡了这么多年脖子，都卡成出口第一了。" 但只要稍微了解一下芯片产业，就知道这个"第一"还远谈不上乐观。 如果我们再看中国进口商品，就会发现， 去年中国第一大进口商品还是芯片 ，其进口额高于我 们刻板印象中大量进口的原油，说中国还很缺芯片一点也不为过。 而且无论是数量还是金额， 芯片进口都远大于出口。 进口芯片平均下来5元一个，出口芯片均价只有3.8元，说明进口芯片比出口芯片高端， 中国缺 的是高端芯片 。 事实也是如此，比如现在的前沿方向AI大模型，需要高端的AI芯片来进行训练和推 ...

Core Viewpoint - The company, Dalian Baiao Chemical Co., Ltd., reported a revenue of 1.312 billion yuan for its industrial biocide business in 2024, reflecting a year-on-year growth of 23.09%. However, the gross profit margin decreased by 8.28 percentage points to 44.30% due to increased competition and pricing pressures in the market [2][5]. Group 1: Financial Performance - The industrial biocide business generated 1.207 billion yuan in revenue, accounting for 92% of the main business income, with over 60% of this revenue coming from overseas markets [2][3]. - The company’s overseas revenue from 2021 to 2024 showed an upward trend, increasing from 471 million yuan in 2021 to 762 million yuan in 2024 [2]. - The average selling price of industrial biocide products decreased by 14.95%, while the unit cost increased by 0.70%, leading to an overall decline in gross profit margin [5][6]. Group 2: Product and Market Analysis - The company specializes in the research, production, and sales of isothiazolinone-based industrial biocides, with no direct competitors listed in the public market [5][6]. - The average sales prices of key products, such as CMIT/DCOIT and BIT series, experienced significant declines, with CMIT/DCOIT prices dropping by 25.03% [5][6]. - The company faced increased competition as domestic manufacturers expanded production capacity, leading to downward pressure on product prices [5][6]. Group 3: Customer and Supply Chain Insights - The company provided details on its top ten overseas customers, including their sales amounts and operational details, confirming that there are no related party transactions with these customers [8][9]. - The logistics and transportation costs for overseas sales have fluctuated significantly, with transportation expenses rising by 129.37% in 2024 compared to the previous year [10][11]. - The company’s overseas business transportation costs were primarily borne by the company, with major carriers being large international shipping companies [10][11]. Group 4: Semiconductor Business Overview - In 2024, the company acquired a 54.63% stake in Chipwise, which achieved a net profit of 103.29% of its performance commitment, indicating strong operational performance [13][14]. - Chipwise's revenue for 2024 reached 543.46 million yuan, with a significant increase in gross profit margin due to successful product lines [16][18]. - The company’s cash flow from operating activities for Chipwise remained negative, primarily due to high procurement costs for semiconductor equipment [17][18].

热点板块：展望 7 月 A 股，可能仍是事件驱动的主题性行情，但板块间将出现高低切换。6 月末创 新药和银行等热门板块出现震荡回调，但 TMT、先进制造等板块开始超跌反弹，虽然 7 月预计仍是事 件驱动的主题性行情，但板块高低切换却是大概率事件。1）促进消费扩大内需是 2025 年的重点任务， 虽然大消费方向年报和一季报表现相对平淡，但市场对后续政策对冲仍有期待，这将是 2025 年大消费 方向的重要看点。关注乳制品、IP 消费、休闲旅游、医美等基本面景气度较高的板块。2）机器人国产 化和走进老百姓生活依然是 2025 年比较确定的趋势，机器人产品将从人形机器人向四足机器人、功能 型机器人扩展。以此带来的传感器、控制器、灵巧手等板块的阶段性机会将会反复出现。7 月特斯拉将 公布财报，且市场预期特斯拉人形机器人版本有可能更新，或将成为机器人板块新催化剂。3）半导体 国产化仍是大势所趋，关注其中的半导体设备、晶圆制造、半导体材料、IC 设计等。4）军工板块 2025 年存在订单回升的预期，大部分军工子板块如地面装备、航空装备、军工电子等一季报已经出现触底迹 象。5）创新药经历了近 4 年的调整后逐步迎来收获期，自 ...

公众号记得加星标⭐️，第一时间看推送不会错过。 来源：内容来自 moneyDJ 。 *免责声明：本文由作者原创。文章内容系作者个人观点，半导体行业观察转载仅为了传达一种不同的观点，不代表半导体行业 观察对该观点赞同或支持，如果有任何异议，欢迎联系半导体行业观察。 END 今天是《半导体行业观察》为您分享的第 4084 期内容，欢迎关注。 AI伺服器用GPU、HBM需求旺盛，加上受惠台积电(2330)将量产2纳米(nm)，日本半导体制造装置 协会(SEAJ)上修2025年度日本制半导体(芯片)设备销售额预估、将续创历史新高纪录，且预估2026 年度销售额将史上首度冲破5兆日圆大关、改写历史新高。 SEAJ 3日公布预估报告指出，因AI伺服器用GPU、HBM需求旺盛，台湾先进晶圆代工厂(台积电)将 开始量产2纳米、对2纳米的投资增加，加上南韩对DRAM/HBM的投资增加，因此2025年度(2025年4 月-2026年3月)日本制芯片设备销售额(指日系企业于日本国内及海外的设备销售额)自前次(2025年1 月)预估的4兆6,590亿日圆上修至4兆8,634亿日圆、将较2024年度增加2.0%，年销售额将连续第2年 ...

交银国际研究 每日晨报 2025 年 7 月 4 日 今日焦点 | 港股策略 | | 全球主要指数 | | | | | --- | --- | --- | --- | --- | --- | | 从多空两维看港股配置方向 | | 宏观策略 | | | 年初至今 | | 李少金 | Evan.Li@bocomgroup.com | | 收盘价 | 升跌% | 升跌% | | | | 恒指 | 24,070 | -0.71 | 16.49 | 2025 上半年港股表现亮眼，恒指和恒生科技指数分别录得 20%和 18.7% 的半年度收益，位居全球主要股指前列。本篇报告从内外资配置偏好变 化以及卖空仓位分布等维度，系统梳理资金流向的一致性与分歧点： 南向资金：均衡配置中的结构性倾斜。南向资金年初至今对港股各板块 持仓均有提升，板块轮动更为显著，从 1 季度的信息技术，再到 2 季度 初的新消费，以及近一个月的主力配置方向集中在医疗保健和金融板块。 外资：聚焦科技。相比之下，外资仅边际主动提升信息技术板块仓位， 其他板块持仓市值多数下降。对科技板块的偏好选择可能反映其对港股 科技企业长期竞争力和估值修复空间的看好。 卖 ...

证券代码：688012 证券简称：中微公司 公告编号：2025-046 中微半导体设备（上海）股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.30元 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。（中微公司回购专用证券账户除外） 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所上市公司自律监管指引第 7号一一回购股份》等相关法律、行政法规、部门规章及其他规范性文件以及《公司章程》的有关规 定，公司回购专用证券账户中的股份不享有股东大会表决权、利润分配、公积金转增股本、认购新股等 权利。 3.差异化分红方案： ● 相关日期 ■ 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025年5月28日的2024年年度股东大会审议通过。 二、分配方案 1.发放年度：2024年年度 2.分派对象： （1）本次差异化分红方案 根据公司2 ...

Group 1 - The company is implementing a "equipment + service" platform development strategy, with a high market share in CMP equipment and successful acceptance of multiple thinning machines and low-energy high-current ion implantation equipment [1][3] - The company plans to expand its wafer regeneration capacity to 600,000 pieces per month, benefiting significantly from the accelerated expansion trend of wafer fabs [1][3] Group 2 - The CMP equipment Universal-H300 has received bulk repeat orders and has achieved large-scale shipments, while specialized CMP equipment for third-generation semiconductor customers has been successfully developed and sent for client verification [1] - The thinning equipment covers various process customers, with the 12-inch ultra-precision wafer thinning machine Versatile-GP300 achieving multiple acceptances to meet customer mass production needs [2] - The company has established a series of cleaning equipment layouts covering large wafers and compound semiconductors, with the HSC-S1300 and HSC-F3400 cleaning equipment successfully verified and sold [2] Group 3 - The company has become a professional foundry for wafer regeneration with Fab equipment and process technology services, currently achieving a wafer regeneration capacity of approximately 200,000 pieces per month [2] - The company plans to build a wafer regeneration expansion project in Kunshan, Jiangsu Province, with a total planned capacity expansion of 400,000 pieces per month, and the first phase of construction capacity is expected to be 200,000 pieces per month with an investment not exceeding 500 million RMB [2] Group 4 - Revenue projections for the company are estimated at 4.503 billion, 5.860 billion, and 7.360 billion RMB for the years 2025 to 2027, with net profits of 1.290 billion, 1.682 billion, and 2.121 billion RMB respectively [3]

金十数据7月3日讯，阿斯麦(ASML.O)预告，将于欧洲中部时间7月16日07:00公布2025年第二季度业 绩，仍比台积电早一天。ASML高层将于欧洲中部时间当日15:00举行60分钟的投资者电话会议。 阿斯麦将于7月16日公布二季报 ...

Group 1: Northern Huachuang (北方华创) - The company is positioned as a leading domestic semiconductor equipment manufacturer, showcasing both growth potential and resilience [1] - The domestic semiconductor equipment market share in China has increased from 13% in 2015 to an estimated 42% in 2024, with Northern Huachuang expected to double its market share by 2025 compared to 2020 [2] - The company’s current valuation at 27 times NTM P/E is close to historical lows, suggesting an attractive investment opportunity with a target price of RMB 530, indicating a potential upside of 19.6% [2] Group 2: Genscript Biotech (云顶新耀) - The company is advancing its platform for reversible mRNA therapies, with promising data from multiple drug candidates [3] - The EVM16 candidate has shown efficacy in mouse models and demonstrated synergy with PD-1 antibodies, while EVM14 is progressing through preclinical studies with potential for inducing immune memory [4] - The EVER001 study for treating membranous nephropathy has reported significant immunological responses, with antibody levels dropping by over 60% after 8-12 weeks [4][7] Group 3: Photovoltaic Industry - Recent policy discussions indicate a shift towards addressing the challenges faced by the photovoltaic industry, with expectations for substantive policies to emerge [8] - The report highlights opportunities for leading photovoltaic manufacturers, particularly in glass and silicon production, as the industry seeks to overcome competitive pressures [8] Group 4: Automotive Industry - The report notes a slowdown in the month-on-month growth of new energy vehicle deliveries, with a 17.7% year-on-year increase across 11 manufacturers [9] - BYD's June sales reached 377,628 units, reflecting an 11% year-on-year growth, while Xiaomi's deliveries exceeded 25,000 units despite slight month-on-month declines [10][11] - The overall market is expected to continue its growth trajectory in July, driven by new model launches from various manufacturers [11]